{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:49:38Z","timestamp":1781812178864,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Rajendra Institute of Technology and Sciences, Sirsa, India"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ejphar.2012.10.012","type":"journal-article","created":{"date-parts":[[2012,10,18]],"date-time":"2012-10-18T03:36:36Z","timestamp":1350531396000},"page":"388-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy"],"prefix":"10.1016","volume":"698","author":[{"given":"Supriya","family":"Kadian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanjaian","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitchai","family":"Balakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2012.10.012_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000075925","article-title":"Cellular lipid metabolism and the role of lipids in progressive renal disease","volume":"24","author":"Abrass","year":"2004","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.mol.0000226115.97436.c0","article-title":"Diabetic dyslipidaemia","volume":"17","author":"Adiels","year":"2006","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/138161209787315701","article-title":"Fibrates and microvascular complications in diabetes\u2014insight from the FIELD study","volume":"15","author":"Ansquer","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2012.10.012_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2012.10.012_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2010.03.002","article-title":"The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy","volume":"636","author":"Arora","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.phrs.2009.02.002","article-title":"Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions","volume":"60","author":"Balakumar","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2012.10.012_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FJC.0b013e3181ad2190","article-title":"Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism","volume":"54","author":"Balakumar","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.phrs.2009.01.010","article-title":"Emerging role of PPAR ligands in the management of diabetic nephropathy","volume":"60","author":"Balakumar","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2012.10.012_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/157339912800563972","article-title":"Telmisartan in the management of diabetic nephropathy: a contemporary view","volume":"8","author":"Balakumar","year":"2012","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.ejphar.2012.10.012_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1470320308098343","article-title":"Experimental models for nephropathy","volume":"9","author":"Balakumar","year":"2008","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.ejphar.2012.10.012_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11010-008-9917-z","article-title":"Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat","volume":"320","author":"Balakumar","year":"2009","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2012.10.012_bib12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.phrs.2012.01.004","article-title":"Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?","volume":"65","author":"Balakumar","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2012.10.012_bib13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.phrs.2012.07.001","article-title":"The combined strategy with PPAR\u03b1 agonism and AT(1) receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat","volume":"66","author":"Bishnoi","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2012.10.012_bib14","first-page":"21","article-title":"Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus","volume":"5","author":"Bonakdaran","year":"2011","journal-title":"Iran. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2012.10.012_bib15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0003-2697(72)90335-1","article-title":"A methodology for analysis of tissue sulfhydryl components","volume":"46","author":"Boyne","year":"1972","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejphar.2012.10.012_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0378-4347(99)00318-7","article-title":"Analysis of creatine and creatinine in urine by capillary electrophoresis","volume":"732","author":"Burke","year":"1999","journal-title":"J. Chromatogr. B.: Biomed. Sci. Appl."},{"key":"10.1016\/j.ejphar.2012.10.012_bib17","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1111\/j.1523-1755.2005.09415.x","article-title":"Role of lipid control in diabetic nephropathy","volume":"94","author":"Chen","year":"2005","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ejphar.2012.10.012_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4093\/dmj.2011.35.4.327","article-title":"Role of peroxisome proliferator-activated receptor \u03b1 in diabetic nephropathy","volume":"35","author":"Chung","year":"2011","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.ejphar.2012.10.012_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2012.10.012_bib20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jdiacomp.2007.12.007","article-title":"The effect of hemodialysis on accelerated atherosclerosis in diabetic patients: correlation of carotid artery intima-media thickness with oxidative stress","volume":"23","author":"Dursun","year":"2009","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.ejphar.2012.10.012_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","article-title":"Tissue sulfhydryl groups","volume":"82","author":"Ellman","year":"1959","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejphar.2012.10.012_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.semnephrol.2007.01.012","article-title":"Histopathology of diabetic nephropathy","volume":"27","author":"Fioretto","year":"2007","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib23","doi-asserted-by":"crossref","unstructured":"Frazier-Wood, A.C., Ordovas, J.M., Straka, R.J., Hixson, J.E., Borecki, I.B., Tiwari, H.K., Arnett, D.K., The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study. Pharmacogenomics J. http:\/\/dx.doi.org\/10.1038\/tpj.2012.9, in press.","DOI":"10.1038\/tpj.2012.9"},{"key":"10.1016\/j.ejphar.2012.10.012_bib24","first-page":"356","article-title":"The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources","volume":"61","author":"Graham","year":"2011","journal-title":"Comp. Med."},{"key":"10.1016\/j.ejphar.2012.10.012_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","article-title":"Diabetic nephropathy: diagnosis, prevention, and treatment","volume":"28","author":"Gross","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2012.10.012_bib26","first-page":"53","article-title":"A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy","volume":"53","author":"Hamada","year":"2007","journal-title":"Kobe. J. Med. Sci."},{"key":"10.1016\/j.ejphar.2012.10.012_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000329383","article-title":"A role for oxidative stress","volume":"174","author":"Heyman","year":"2011","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib28","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.ejphar.2012.10.012_bib29","first-page":"S12","article-title":"Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control","volume":"10","author":"Hunsicker","year":"2004","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.ejphar.2012.10.012_bib30","first-page":"64","article-title":"Serum creatinine and creatinine clearance to estimate renal function in essential hypertension","volume":"26","author":"Jabary","year":"2006","journal-title":"Nefrologia"},{"key":"10.1016\/j.ejphar.2012.10.012_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3181\/0705-MR-134","article-title":"Diabetic nephropathy: mechanisms of renal disease progression","volume":"233","author":"Kanwar","year":"2008","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.ejphar.2012.10.012_bib32","first-page":"S419","article-title":"Protection against nephropathy with fenofibrate in type 2 diabetes mellitus: the FIELD study","volume":"120","author":"Keech","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2012.10.012_bib33","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1681\/ASN.2007010089","article-title":"Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet","volume":"18","author":"Kume","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib34","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.diabres.2005.03.015","article-title":"The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?","volume":"68","author":"Leiter","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2012.10.012_bib35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1159\/000097368","article-title":"HGF protects rat mesangial cells from high-glucose-mediated oxidative stress","volume":"26","author":"Li","year":"2006","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1258\/ebm.2009.009218","article-title":"Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-\u03baB and transforming growth factor-\u03b21\/Smad3 in diabetic nephropathy","volume":"235","author":"Li","year":"2010","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.ejphar.2012.10.012_bib37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1751-7176.2011.00434.x","article-title":"Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection","volume":"13","author":"Long","year":"2011","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ejphar.2012.10.012_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4239\/wjd.v3.i1.7","article-title":"Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy","volume":"3","author":"Luis-Rodr\u00edguez","year":"2012","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.ejphar.2012.10.012_bib39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0733-8627(20)30997-4","article-title":"Blood urea nitrogen and creatinine","volume":"4","author":"Lyman","year":"1986","journal-title":"Emerg. Med. Clin. North Am."},{"key":"10.1016\/j.ejphar.2012.10.012_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1042\/BA20080086","article-title":"Renal oxidative stress and nitric oxide production in streptozotocin-induced diabetic nephropathy in rats: the possible modulatory effects of garlic (Allium sativum L.)","volume":"52","author":"Mariee","year":"2009","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.ejphar.2012.10.012_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","article-title":"Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction","volume":"95","author":"Ohkawa","year":"1979","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejphar.2012.10.012_bib42","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/sj.ki.5000209","article-title":"PPARalpha agonist fenofibrate improves diabetic nephropathy in db\/db mice","volume":"69","author":"Park","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2012.10.012_bib43","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/clinchem\/38.10.1933","article-title":"Serum creatinine as an index of renal function: new insights into old concepts","volume":"38","author":"Perrone","year":"1992","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejphar.2012.10.012_bib44","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/ki.2010.513","article-title":"Need for better diabetes treatment for improved renal outcome","volume":"120","author":"Rossing","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ejphar.2012.10.012_bib45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrneph.2010.59","article-title":"Role of triglyceride-rich lipoproteins in diabetic nephropathy","volume":"6","author":"Rutledge","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib46","doi-asserted-by":"crossref","first-page":"34L","DOI":"10.1016\/j.amjcard.2008.09.073","article-title":"After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate","volume":"102","author":"Sacks","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib47","first-page":"176","article-title":"Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients","volume":"16","author":"Shelbaya","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2012.10.012_bib48","first-page":"135","article-title":"Renoprotection by telmisartan versus benazepril in streptozotocin induced diabetic nephropathy","volume":"5","author":"Singh","year":"2006","journal-title":"Iran. J. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2012.10.012_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.crd.0000188034.76283.5e","article-title":"Management of dyslipidemia in diabetes","volume":"14","author":"Solano","year":"2006","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.ejphar.2012.10.012_bib50","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/01.HYP.26.6.869","article-title":"Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update","volume":"26","author":"Sowers","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2012.10.012_bib51","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ajpath.2011.05.016","article-title":"Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy","volume":"179","author":"Thompson","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib52","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1681\/ASN.2005121320","article-title":"Lipids and renal disease","volume":"17","author":"Trevisan","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000326849","article-title":"Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus","volume":"34","author":"Wanner","year":"2011","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.ejphar.2012.10.012_bib54","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00228-009-0723-7","article-title":"Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report","volume":"65","author":"Wu","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.10.012_bib55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1758-5996-1-10","article-title":"Diabetic nephropathy","volume":"1","author":"Zelmanovitz","year":"2009","journal-title":"Diabetol. Metab. Syndr."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912008588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912008588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:16:10Z","timestamp":1757974570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299912008588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":55,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0014299912008588"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2012.10.012","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2012.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}